218 related articles for article (PubMed ID: 17244172)
1. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
Buckley PF; Stahl SM
Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
[TBL] [Abstract][Full Text] [Related]
2. [Influences of second generation antipsychotics on the course of schizophrenia].
Messer T
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S161-3. PubMed ID: 15570540
[TBL] [Abstract][Full Text] [Related]
3. Negative symptoms of schizophrenia: a problem that will not go away.
Stahl SM; Buckley PF
Acta Psychiatr Scand; 2007 Jan; 115(1):4-11. PubMed ID: 17201860
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of schizophrenia: ploypharmacy approaches.
Rahiminejad F; Akhondzadeh S
Acta Med Iran; 2010; 48(4):203-8. PubMed ID: 21279929
[TBL] [Abstract][Full Text] [Related]
5. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
[TBL] [Abstract][Full Text] [Related]
6. [Second generation of neuroleptics--expectations and the reality].
Jarema M
Psychiatr Pol; 2002; 36(6 Suppl):209-16. PubMed ID: 12647441
[TBL] [Abstract][Full Text] [Related]
7. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of new generation antipsychotics in adolescent patients.
Arango C; Parellada M; Moreno DM
Eur Neuropsychopharmacol; 2004 Nov; 14 Suppl 4():S471-9. PubMed ID: 15572266
[TBL] [Abstract][Full Text] [Related]
9. [Current concepts of pharmacological treatment in schizophrenia].
Jarema M
Psychiatr Pol; 2002; 36(6):857-68. PubMed ID: 12725017
[TBL] [Abstract][Full Text] [Related]
10. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
11. Algorithm for the treatment of negative symptoms in chronic schizophrenia.
Tsutsumi T; Uchimura H
Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S15-7. PubMed ID: 10560892
[TBL] [Abstract][Full Text] [Related]
12. Do negative symptoms respond to pharmacological treatment?
Kane JM; Mayerhoff D
Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914
[No Abstract] [Full Text] [Related]
13. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
14. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
[TBL] [Abstract][Full Text] [Related]
15. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics and polydipsia: a cause or a treatment?
Bersani G; Pesaresi L; Orlandi V; Gherardelli S; Pancheri P
Hum Psychopharmacol; 2007 Mar; 22(2):103-7. PubMed ID: 17335101
[TBL] [Abstract][Full Text] [Related]
17. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
Nikam SS; Awasthi AK
Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
[TBL] [Abstract][Full Text] [Related]
18. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia.
Taylor D; Hayhurst K; Kerwin R
Int Clin Psychopharmacol; 2007 May; 22(3):133-6. PubMed ID: 17414738
[TBL] [Abstract][Full Text] [Related]
19. Sexual dysfunction in schizophrenia: focus on recent evidence.
Baggaley M
Hum Psychopharmacol; 2008 Apr; 23(3):201-9. PubMed ID: 18338766
[TBL] [Abstract][Full Text] [Related]
20. Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia.
Buie LW; Oertel MD; Cala SO
Ann Pharmacother; 2006 Dec; 40(12):2200-4. PubMed ID: 17119103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
